Clinical Laserthermia Systems AB (FRA:LS60) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Clinical Laserthermia Systems AB EBITDA Margin % Related Terms
Clinical Laserthermia Systems AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinical Laserthermia Systems AB EBITDA Margin % Chart
FRA:LS60 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Clinical Laserthermia Systems AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinical Laserthermia Systems AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Clinical Laserthermia Systems AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Clinical Laserthermia Systems AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinical Laserthermia Systems AB (FRA:LS60) has a EBITDA Margin % of -531.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clinical Laserthermia Systems AB and its competitors. According to the industry distribution chart, Clinical Laserthermia Systems AB ranks #719 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 88.1%.
Is Clinical Laserthermia Systems AB's EBITDA Margin % too high?
Clinical Laserthermia Systems AB's current EBITDA Margin % is -531.36%. Based on the distribution chart, Clinical Laserthermia Systems AB ranks #719 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Clinical Laserthermia Systems AB has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Clinical Laserthermia Systems AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Clinical Laserthermia Systems AB ranks #719 out of 816 companies for EBITDA Margin %. This places Clinical Laserthermia Systems AB in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clinical Laserthermia Systems AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinical Laserthermia Systems AB's current EBITDA Margin % is -531.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinical Laserthermia Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB (FRA:LS60) is currently considered Fairly Valued. The stock's GF Value™ is €0.29, compared to a current price of €0.27 — trading 7.9% below its estimated fair value. The current EBITDA Margin % is -531.36%. Clinical Laserthermia Systems AB's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Clinical Laserthermia Systems AB (FRA:LS60), the current EBITDA Margin % is -531.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinical Laserthermia Systems AB (FRA:LS60) Overvalued in 2026?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB stock appears to be undervalued.
The current stock price of €0.27 is trading 7.9% below its estimated GF Value™ of €0.29.
GuruFocus considers Clinical Laserthermia Systems AB to be Fairly Valued.
Key valuation signals for FRA:LS60:
EBITDA Margin %: -531.36%
GF Value™: €0.29 vs. price of €0.27 (7.9% below fair value)
No single metric tells the full story. See the FRA:LS60 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinical Laserthermia Systems AB Business Description
Clinical Laserthermia Systems AB develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe.
36GF Score
Get the complete analysis for FRA:LS60
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LS60 has been successfully added to your 
